❇️ Of all the organs that decline with age, the brain tends to get the most attention — and for good reason. Cognitive decline, neurodegeneration, and the slow erosion of mental sharpness are among the most feared aspects of aging. Cortagen is a short-chain peptide bioregulator from the Khavinson series specifically targeted at cerebral cortex tissue, and its research profile covers neuroprotection, neuronal preservation, and brain aging in ways that set it apart from better-known nootropic peptides. ❇️ What Is Cortagen? Cortagen is a short-chain peptide bioregulator developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of the same organ-specific series as Cardiogen (heart), Bronchogen (lungs), and Pancreagen (pancreas). Its target tissue is the cerebral cortex — the brain's outermost layer responsible for higher-order functions including memory, reasoning, language, and sensory processing. Like other Khavinson bioregulators, Cortagen is thought to work at the chromatin level — binding to DNA-associated proteins in cortical neurons and modulating gene expression toward a more youthful, repair-competent state. The goal isn't stimulation in the nootropic sense; it's tissue-level restoration of the neural environment that supports healthy function over the long term. 🔬 Key Research Findings Research in aging animal models and early investigational settings has highlighted several relevant effects: • Neuroprotection under ischemic conditions: Studies in animal stroke models demonstrated that cortical peptide bioregulator treatment reduced neuronal death in the ischemic penumbra — the at-risk zone surrounding a stroke injury — suggesting a meaningful cytoprotective effect in the cortex. • Reduced neuronal apoptosis: Cortagen has been associated with downregulation of pro-apoptotic signaling in cortical neurons under oxidative and excitotoxic stress conditions, helping preserve the non-renewable pool of cortical cells. • Antioxidant upregulation in neural tissue: The brain consumes roughly 20% of the body's oxygen despite being only 2% of body weight — making it uniquely vulnerable to oxidative damage. Research shows Cortagen supports antioxidant enzyme activity in cortical tissue, reducing lipid peroxidation and oxidative stress accumulation.

Just wanted to share that I finally broke my 6 month long stall on max tirz by adding Cagri that I got from PRC. It’s good stuff and working wonderfully. I just put in my second order at PRC for my next set of experiments. I’m really impressed with the pricing and quality as well as the extensive list of outside vendors provided. I’m so glad I stumbled upon this community when I joined skool. I had no idea you existed previously.

We welcomed or 100th member and we are so STOKED to see our community grow ☀️ to celebrate we are giving away a Dream Stack. 📣 One lucky winner will get their Peptide Resource Center Dream Stack! ❇️ Rules: 1. Must be 21 (sorry kiddos...) 2. Must be a US resident (bc shipping y'all) 3. Must be a PRC Skool member (if you are reading this, you are) ❇️ How to enter: 1. Comment below your DREAM STACK, if you win that's what you could get!!! 🔸 Limited to items in stock at PeptideResourceCenter.com website BUT we might be able to accommodate hard to find items... 🔸 Only one vial per research peptide in the stack. 🔸 Up to a $500.00 value. 📣 The giveaway: ➡ We will use an app to pick a randon name from the entries received. ➡ Winner will be announced on: July 15, 2026. ➡ Winner will receive their Dream Stack by mail after winner is announced.

❇️ The heart beats roughly 100,000 times a day for a lifetime — and like every other organ, its capacity to repair and maintain itself declines with age. Cardiogen is a cardiac-specific peptide bioregulator from the Khavinson series designed to address exactly that. With research touching on ischemic protection, cardiomyocyte preservation, and anti-fibrotic signaling, it's one of the more compelling compounds for anyone studying cardiovascular aging. ❇️ What Is Cardiogen? Cardiogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Arg / AEDR) developed at the St. Petersburg Institute of Bioregulation and Gerontology. Like all Khavinson bioregulators, it was designed to be tissue-specific — in this case targeting myocardial (heart muscle) cells. The compound is thought to work by binding to chromatin in cardiac cells and modulating gene transcription, promoting the expression of proteins involved in cellular repair, stress resistance, and structural integrity of the myocardium. The heart is predominantly made up of terminally differentiated cells — cardiomyocytes that can't easily be replaced once lost. This makes the preservation of existing cardiac tissue especially important, and it's the core rationale behind Cardiogen's research focus. 🔬 Key Research Findings Preclinical studies on Cardiogen and related cardiac bioregulators have produced meaningful data across several areas: • Cardioprotection in ischemia-reperfusion models: Research in animal models showed that pre-treatment with cardiac peptide bioregulators significantly reduced cardiomyocyte death following ischemia-reperfusion injury — the type of damage that occurs during a heart attack and its aftermath. • Reduced cardiomyocyte apoptosis: Cardiogen has been shown to downregulate apoptotic signaling in cardiac tissue under stress conditions, helping preserve the limited pool of functional heart muscle cells. • Anti-fibrotic signaling: Cardiac fibrosis — the replacement of functional muscle with scar tissue — is a hallmark of aging and post-injury remodeling. Studies suggest Cardiogen may help reduce fibrotic marker expression in myocardial tissue.

❇️ The lungs are one of the most oxidatively stressed organs in the body — constantly exposed to environmental toxins, pollutants, and the wear of decades of breathing. Yet respiratory health rarely makes it into peptide conversations. Bronchogen is a lung-targeted peptide bioregulator from the Khavinson series that's quietly building a research case for pulmonary tissue support, anti-fibrotic potential, and age-related respiratory decline. ❇️ What Is Bronchogen? Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu / AEDL) developed at the St. Petersburg Institute of Bioregulation and Gerontology as part of the same organ-specific peptide series that includes Pancreagen, Crystagen, Thymalin, and others. Each compound in this series is derived from or designed to mimic peptides isolated from specific tissue extracts, with the goal of restoring youthful gene expression patterns in the corresponding organ. Bronchogen's target is the bronchial epithelium and pulmonary tissue. It's thought to bind to chromatin in lung cells and upregulate gene expression related to cellular repair, antioxidant defense, and structural maintenance — essentially signaling aging lung cells to behave more like they did earlier in life. 🧬 Key Research Findings Preclinical and investigational research has pointed to several meaningful effects in pulmonary tissue: • Reduced pulmonary fibrosis markers: In animal models, Bronchogen treatment was associated with decreased fibrotic tissue formation in the lungs — a significant finding given how central fibrosis is to conditions like idiopathic pulmonary fibrosis and post-infection scarring. • Antioxidant upregulation: Like other bioregulators in this series, Bronchogen has demonstrated the ability to increase antioxidant enzyme activity (notably SOD and catalase) in pulmonary tissue, reducing oxidative damage accumulation. • Preservation of bronchial epithelial integrity: Histological studies in aging models showed better-maintained ciliary function and bronchial cell architecture in treated subjects, supporting airway clearance mechanisms.